Cite
Goto S, Goto S. Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?. Eur Heart J Cardiovasc Pharmacother. 2015;1(2):83-5doi: 10.1093/ehjcvp/pvu017.
Goto, S., & Goto, S. (2015). Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?. European heart journal. Cardiovascular pharmacotherapy, 1(2), 83-5. https://doi.org/10.1093/ehjcvp/pvu017
Goto, Shinichi, and Goto, Shinya. "Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?." European heart journal. Cardiovascular pharmacotherapy vol. 1,2 (2015): 83-5. doi: https://doi.org/10.1093/ehjcvp/pvu017
Goto S, Goto S. Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):83-5. doi: 10.1093/ehjcvp/pvu017. Epub 2015 Feb 19. PMID: 27533975.
Copy
Download .nbib
